

collection: There are an estimated 1,556 total annual burden hours associated with this collection.

*If additional information is required contact:* Mrs. Lynn Murray, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street, NE., Suite 2E-502, Washington, DC 20530.

Dated: February 9, 2011.

**Lynn Murray,**

*Department Clearance Officer, PRA, U.S. Department of Justice.*

[FR Doc. 2011-3298 Filed 2-14-11; 8:45 am]

**BILLING CODE 4410-18-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[OMB Number 1117-0043]

#### Agency Information Collection

**Activities: Proposed Collection;**

**Comments Requested: Drug**

**Questionnaire, DEA Form 341**

**ACTION:** 30-Day Notice of Information Collection under Review.

The Department of Justice (DOJ), Drug Enforcement Administration (DEA) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the **Federal Register** Volume 75, Number 239, page 77906 on December 14, 2010, allowing for a 60-day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until March 17, 2011. This process is conducted in accordance with 5 CFR 1320.10.

If you have comments, especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Raymond A. Pagliarini, Jr., Assistant Administrator, Human Resources Division, Drug Enforcement Administration, 8701 Morrisette Drive, Springfield, VA 22152.

Written comments concerning this information collection should be sent to the Office of Information and Regulatory Affairs, Office of Management and Budget, Attn: DOJ Desk Officer. The best way to ensure your comments are

received is to e-mail them to [aira\\_submission@omb.eop.gov](mailto:aira_submission@omb.eop.gov) or fax them to 202-395-7285. All comments should reference the 8 digit OMB number for the collection or the title of the collection. If you have questions concerning the collection, please call Raymond A. Pagliarini, Jr., Assistant Administrator, Human Resources Division, Drug Enforcement Administration, 8701 Morrisette Drive, Springfield, VA 22152 or the DOJ Desk Officer at 202-395-3176.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility, and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

#### *Overview of this Information Collection 1117-0043:*

(1) *Type of Information Collection:* Extension of a currently approved collection.

(2) *Title of the Form/Collection:* Drug Questionnaire (DEA Form 341).

(3) *Agency form number, if any, and the applicable component of the Department sponsoring the collection:*

*Form number:* DEA Form 341.

*Component:* Human Resources Division, Drug Enforcement Administration, U.S. Department of Justice.

(4) *Affected public who will be asked or required to respond, as well as a brief abstract:*

*Primary:* Individuals.

*Other:* None.

*Abstract:* DEA Policy states that a past history of illegal drug use may be a disqualification for employment with DEA. This form asks job applicants specific questions about their personal history, if any, of illegal drug use.

(5) *An estimate of the total number of respondents and the amount of time*

*estimated for an average respondent to respond:* It is estimated that 173,800 respondents will respond annually, taking 5 minutes to complete each form.

(6) *An estimate of the total public burden (in hours) associated with the collection:* 14,483 annual burden hours.

*If additional information is required contact:* Lynn Murray, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, 145 N Street, NE., Suite 2E-502, Washington, DC 20530.

Dated: February 9, 2011.

**Lynn Murray,**

*Department Clearance Officer, Department of Justice.*

[FR Doc. 2011-3319 Filed 2-14-11; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Importer of Controlled Substances; Notice of Registration

By Notice dated November 1, 2010, and published in the **Federal Register** on November 12, 2010, 75 FR 69459, Formulation Technologies LLC., 11501 Domain Drive, Suite 130, Austin, Texas 78758, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Fentanyl (9801), a basic class of controlled substance listed in schedule II.

The company plans to import the listed controlled substance for analytical characterization, secondary packaging, and for distribution to clinical trial sites.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Formulation Technologies LLC. to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Formulation Technologies LLC. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of

the basic class of controlled substance listed.

Dated: February 4, 2011.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of  
Diversion Control, Drug Enforcement  
Administration.*

[FR Doc. 2011-3409 Filed 2-14-11; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Importer of Controlled Substances; Notice of Registration

By Notice dated November 1, 2010,  
and published in the **Federal Register**  
on November 12, 2010, 75 FR 69459,

Cerilliant Corporation, 811 Paloma  
Drive, Suite A, Round Rock, Texas  
78665-2402, made application by  
renewal to the Drug Enforcement  
Administration (DEA) to be registered as  
an importer of the following basic  
classes of controlled substances:

Drug	Schedule
Cathinone (1235) .....	I
Methcathinone (1237) .....	I
N-Ethylamphetamine (1475) .....	I
N,N-Dimethylamphetamine (1480) .....	I
Fenethylamine (1503) .....	I
Gamma Hydroxybutyric Acid (2010) .....	I
Ibogaine (7260) .....	I
Lysergic acid diethylamide (7315) .....	I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) .....	I
Marihuana (7360) .....	I
Tetrahydrocannabinols (7370) .....	I
Mescaline (7381) .....	I
3,4,5-Trimethoxyamphetamine (7390) .....	I
4-Bromo-2,5-dimethoxyamphetamine (7391) .....	I
4-Bromo-2,5-dimethoxyphenethylamine (7392) .....	I
4-Methyl-2,5-dimethoxyamphetamine (7395) .....	I
2,5-Dimethoxyamphetamine (7396) .....	I
3,4-Methylenedioxymphetamine (7400) .....	I
3,4-Methylenedioxy-N-ethylamphetamine (7404) .....	I
3,4-Methylenedioxymethamphetamine (7405) .....	I
4-Methoxyamphetamine (7411) .....	I
Alpha-methyltryptamine (7432) .....	I
Diethyltryptamine (7434) .....	I
Dimethyltryptamine (7435) .....	I
Psilocybin (7437) .....	I
Psilocyn (7438) .....	I
5-Methoxy-N,N-diisopropyltryptamine (7439) .....	I
N-Benzylpiperazine (7493) .....	I
Etorphine (except HCl)(9056) .....	I
Heroin (9200) .....	I
Morphine-N-oxide (9307) .....	I
Normorphine (9313) .....	I
Pholcodine (9314) .....	I
Dextromoramide (9613) .....	I
Dipipanone (9622) .....	I
Racemoramide (9645) .....	I
Trimeperidine (9646) .....	I
Tilidine (9750) .....	I
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Methylphenidate (1724) .....	II
Amobarbital (2125) .....	II
Pentobarbital (2270) .....	II
Secobarbital (2315) .....	II
Phencyclidine (7471) .....	II
Phenylacetone (8501) .....	II
Cocaine (9041) .....	II
Codeine (9050) .....	II
Dihydrocodeine (9120) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Benzoyllecgonine (9180) .....	II
Ethylmorphine (9190) .....	II
Meperidine (9230) .....	II
Methadone (9250) .....	II
Dextropropoxyphene, bulk (non-dosage forms) (9273) .....	II
Morphine (9300) .....	II
Oripavine (9330) .....	II
Thebaine (9333) .....	II
Levo-alphaacetylmethadol (9648) .....	II
Oxymorphone (9652) .....	II
Poppy Straw Concentrate (9670) .....	II
Fentanyl (9801) .....	II